Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Trinomia
- Development stage
- Unknown
- Lead developer
- Ferrer
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Trinomia is a fixed-dose combination (polypill) medication developed by the Spanish National Center for Cardiovascular Research (CNIC) in collaboration with Ferrer for the secondary prevention of major adverse cardiovascular events (MACE). It contains three active ingredients: aspirin (an antiplatelet agent), ramipril (an ACE inhibitor), and atorvastatin (an HMG-CoA reductase inhibitor). The polypill strategy is designed to simplify complex treatment regimens for patients who have experienced a myocardial infarction, thereby improving medication adherence—a critical factor in long-term cardiovascular outcomes. Clinical evidence from the Phase 3 SECURE trial demonstrated that Trinomia significantly reduces the risk of MACE and cardiovascular mortality in elderly patients compared to standard usual care.
- Brand names
- TrinomiaSincroniumIltria
- Other names
- Aspirin + Ramipril + AtorvastatinFDC Aspirin/Ramipril/Atorvastatin
02
Targets
PTGS2 (Prostaglandin-Endoperoxide Synthase 2)HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)OATP1B1 (Organic anion transporting polypeptide 1B1)CYP3A4 (Cytochrome P450 3A4)ACE (Angiotensin Converting Enzyme)ACE2 (Angiotensin-converting enzyme 2)
Beyond the preview
Go deeper on Trinomia.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Trinomia.